Stem definition | Drug id | CAS RN |
---|---|---|
beta-lactamase inhibitors | 669 | 58001-44-8 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 43 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 31.38 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 75 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.22 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 3.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.91 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.90 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 6, 1984 | FDA | DR REDDYS LABS INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Bronchiectasis | 116.97 | 20.07 | 41 | 4354 | 10242 | 50590487 |
Bone erosion | 111.84 | 20.07 | 41 | 4354 | 11646 | 50589083 |
Acute generalised exanthematous pustulosis | 76.86 | 20.07 | 29 | 4366 | 8909 | 50591820 |
Hypothyroidism | 75.16 | 20.07 | 43 | 4352 | 34082 | 50566647 |
Neutropenia | 56.82 | 20.07 | 67 | 4328 | 147898 | 50452831 |
Anaphylactic reaction | 54.89 | 20.07 | 42 | 4353 | 54013 | 50546716 |
Drug hypersensitivity | 54.30 | 20.07 | 86 | 4309 | 250924 | 50349805 |
Nail dystrophy | 44.65 | 20.07 | 11 | 4384 | 800 | 50599929 |
Loss of personal independence in daily activities | 43.45 | 20.07 | 41 | 4354 | 70009 | 50530720 |
Hepatitis cholestatic | 39.04 | 20.07 | 16 | 4379 | 6101 | 50594628 |
Cholecystitis chronic | 38.04 | 20.07 | 18 | 4377 | 9651 | 50591078 |
Axillary pain | 37.35 | 20.07 | 11 | 4384 | 1573 | 50599156 |
Jaundice | 32.35 | 20.07 | 23 | 4372 | 26406 | 50574323 |
Pruritus | 32.32 | 20.07 | 74 | 4321 | 283494 | 50317235 |
Catheter site haemorrhage | 31.15 | 20.07 | 11 | 4384 | 2799 | 50597930 |
Toxic skin eruption | 29.73 | 20.07 | 16 | 4379 | 11235 | 50589494 |
Red blood cell sedimentation rate abnormal | 29.17 | 20.07 | 18 | 4377 | 16325 | 50584404 |
Hyperleukocytosis | 29.15 | 20.07 | 7 | 4388 | 457 | 50600272 |
Cholestasis | 28.57 | 20.07 | 21 | 4374 | 25380 | 50575349 |
Appendicitis | 25.04 | 20.07 | 12 | 4383 | 6612 | 50594117 |
Synovitis | 22.08 | 20.07 | 39 | 4356 | 123826 | 50476903 |
Thrombotic microangiopathy | 21.84 | 20.07 | 12 | 4383 | 8779 | 50591950 |
Joint stiffness | 21.22 | 20.07 | 19 | 4376 | 30289 | 50570440 |
Hyperchlorhydria | 20.90 | 20.07 | 7 | 4388 | 1521 | 50599208 |
Meningitis aseptic | 20.32 | 20.07 | 9 | 4386 | 4143 | 50596586 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hepatocellular injury | 89.68 | 26.57 | 43 | 2848 | 21200 | 29550436 |
Cholestasis | 57.45 | 26.57 | 33 | 2858 | 23429 | 29548207 |
Urethral valves | 54.89 | 26.57 | 11 | 2880 | 272 | 29571364 |
Spinal muscular atrophy | 42.98 | 26.57 | 9 | 2882 | 278 | 29571358 |
Pneumococcal sepsis | 42.64 | 26.57 | 11 | 2880 | 855 | 29570781 |
Anaphylactic shock | 41.55 | 26.57 | 22 | 2869 | 13314 | 29558322 |
Anaphylactic reaction | 40.35 | 26.57 | 28 | 2863 | 27545 | 29544091 |
Stevens-Johnson syndrome | 37.18 | 26.57 | 22 | 2869 | 16475 | 29555161 |
Meningitis aseptic | 35.59 | 26.57 | 12 | 2879 | 2364 | 29569272 |
Kounis syndrome | 34.51 | 26.57 | 11 | 2880 | 1818 | 29569818 |
Ischaemic cerebral infarction | 31.77 | 26.57 | 9 | 2882 | 996 | 29570640 |
Motor neurone disease | 30.04 | 26.57 | 7 | 2884 | 356 | 29571280 |
Increased bronchial secretion | 27.75 | 26.57 | 9 | 2882 | 1572 | 29570064 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anaphylactic reaction | 92.31 | 18.52 | 66 | 6191 | 68598 | 64423877 |
Hepatocellular injury | 88.66 | 18.52 | 55 | 6202 | 45180 | 64447295 |
Cholestasis | 84.01 | 18.52 | 53 | 6204 | 44819 | 64447656 |
Acute generalised exanthematous pustulosis | 73.59 | 18.52 | 33 | 6224 | 14025 | 64478450 |
Bone erosion | 56.83 | 18.52 | 26 | 6231 | 11569 | 64480906 |
Meningitis aseptic | 55.86 | 18.52 | 21 | 6236 | 5709 | 64486766 |
Bronchiectasis | 51.91 | 18.52 | 26 | 6231 | 14114 | 64478361 |
Kounis syndrome | 48.29 | 18.52 | 16 | 6241 | 3009 | 64489466 |
Anaphylactic shock | 45.01 | 18.52 | 31 | 6226 | 30297 | 64462178 |
Jaundice | 44.09 | 18.52 | 37 | 6220 | 48475 | 64444000 |
Stevens-Johnson syndrome | 43.87 | 18.52 | 32 | 6225 | 34217 | 64458258 |
Nail dystrophy | 43.41 | 18.52 | 11 | 6246 | 802 | 64491673 |
Spinal muscular atrophy | 42.82 | 18.52 | 9 | 6248 | 285 | 64492190 |
Hepatitis cholestatic | 40.69 | 18.52 | 21 | 6236 | 12134 | 64480341 |
Drug hypersensitivity | 39.11 | 18.52 | 77 | 6180 | 237738 | 64254737 |
Pneumococcal sepsis | 38.26 | 18.52 | 11 | 6246 | 1293 | 64491182 |
Pruritus | 36.38 | 18.52 | 88 | 6169 | 312312 | 64180163 |
Axillary pain | 35.18 | 18.52 | 11 | 6246 | 1721 | 64490754 |
Toxic epidermal necrolysis | 33.05 | 18.52 | 28 | 6229 | 37138 | 64455337 |
Hypothyroidism | 32.98 | 18.52 | 29 | 6228 | 40428 | 64452047 |
Liver injury | 29.63 | 18.52 | 24 | 6233 | 29908 | 64462567 |
Jaundice cholestatic | 29.07 | 18.52 | 15 | 6242 | 8655 | 64483820 |
Motor neurone disease | 28.76 | 18.52 | 7 | 6250 | 432 | 64492043 |
Neutropenia | 27.32 | 18.52 | 67 | 6190 | 239557 | 64252918 |
Clostridium difficile colitis | 25.21 | 18.52 | 21 | 6236 | 27202 | 64465273 |
Aspartate aminotransferase increased | 24.96 | 18.52 | 43 | 6214 | 119745 | 64372730 |
Bronchospasm | 24.94 | 18.52 | 19 | 6238 | 21663 | 64470812 |
Catheter site haemorrhage | 24.73 | 18.52 | 11 | 6246 | 4580 | 64487895 |
Stoma closure | 24.67 | 18.52 | 5 | 6252 | 132 | 64492343 |
Respiratory tract infection bacterial | 24.40 | 18.52 | 7 | 6250 | 816 | 64491659 |
Purpura | 24.11 | 18.52 | 17 | 6240 | 17229 | 64475246 |
Increased bronchial secretion | 22.65 | 18.52 | 9 | 6248 | 2833 | 64489642 |
Drug reaction with eosinophilia and systemic symptoms | 22.46 | 18.52 | 27 | 6230 | 54190 | 64438285 |
Resuscitation | 21.76 | 18.52 | 8 | 6249 | 2043 | 64490432 |
Ischaemic cerebral infarction | 21.68 | 18.52 | 8 | 6249 | 2064 | 64490411 |
Bronchial disorder | 21.52 | 18.52 | 8 | 6249 | 2107 | 64490368 |
Joint stiffness | 21.26 | 18.52 | 20 | 6237 | 30384 | 64462091 |
Lower respiratory tract infection bacterial | 21.18 | 18.52 | 6 | 6251 | 668 | 64491807 |
Rash | 21.01 | 18.52 | 94 | 6163 | 458455 | 64034020 |
Cholangitis | 20.80 | 18.52 | 13 | 6244 | 10789 | 64481686 |
Hepatitis acute | 20.60 | 18.52 | 14 | 6243 | 13375 | 64479100 |
Sputum increased | 20.52 | 18.52 | 9 | 6248 | 3626 | 64488849 |
Alanine aminotransferase increased | 20.41 | 18.52 | 43 | 6214 | 138988 | 64353487 |
Toxic skin eruption | 20.23 | 18.52 | 16 | 6241 | 19268 | 64473207 |
Cholecystitis chronic | 19.98 | 18.52 | 12 | 6245 | 9275 | 64483200 |
Circulatory collapse | 19.50 | 18.52 | 20 | 6237 | 33712 | 64458763 |
Brain injury | 19.20 | 18.52 | 12 | 6245 | 9953 | 64482522 |
Disease complication | 19.16 | 18.52 | 9 | 6248 | 4246 | 64488229 |
Hyperbilirubinaemia | 18.89 | 18.52 | 16 | 6241 | 21189 | 64471286 |
None
Source | Code | Description |
---|---|---|
FDA MoA | N0000000202 | beta Lactamase Inhibitors |
FDA EPC | N0000175930 | beta Lactamase Inhibitor |
CHEBI has role | CHEBI:35474 | anti-anxiety agents |
CHEBI has role | CHEBI:35625 | beta-lactamase inhibitors |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:33281 | antibiotics |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D065093 | beta-Lactamase Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Septicemia due to Escherichia coli | indication | 9323009 | |
Bacterial septicemia | indication | 10001005 | DOID:0040085 |
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Staphylococcal pneumonia | indication | 22754005 | |
Bacterial pneumonia | indication | 53084003 | DOID:874 |
Klebsiella cystitis | indication | 60867007 | |
Pneumonia due to Klebsiella pneumoniae | indication | 64479007 | |
Urinary tract infectious disease | indication | 68566005 | |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Infection due to Escherichia coli | indication | 71057007 | |
Rhinoscleroma | indication | 72409005 | DOID:11336 |
Acute bacterial sinusitis | indication | 75498004 | |
Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
Pneumococcal pneumonia | indication | 233607000 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Bacterial urinary infection | indication | 312124009 | |
Infective otitis media | indication | 312218008 | |
Infection due to Staphylococcus aureus | indication | 406602003 | |
Osteomyelitis due to Staphylococcus aureus | indication | 428783003 | |
Pneumonia due to Staphylococcus aureus | indication | 441658007 | |
Sepsis due to Staphylococcus aureus | indication | 448417001 | |
Sepsis due to Pseudomonas | indication | 448813005 | |
Bacteroides Endometritis | indication | ||
Pneumococcal Acute Otitis Media | indication | ||
Haemophilus Parainfluenzae Pneumonia | indication | ||
Pseudomonas Aeruginosa Urinary Tract Infection | indication | ||
Klebsiella Endometritis | indication | ||
Klebsiella Pneumoniae Peritonitis | indication | ||
Haemophilus Influenzae Acute Otitis Media | indication | ||
Moraxella Catarrhalis Pneumonia | indication | ||
Moraxella Catarrhalis Acute Otitis Media | indication | ||
Staphylococcus Aureus Joint Infection | indication | ||
Staphylococcus Aureus Urinary Tract Infection | indication | ||
E. Coli Peritonitis | indication | ||
Enterobacter Endometritis | indication | ||
Bacteroides Peritonitis | indication | ||
Serratia Urinary Tract Infection | indication | ||
Citrobacter Urinary Tract Infection | indication | ||
Staphylococcus Endometritis | indication | ||
E. Coli Endometritis | indication | ||
Acute otitis media | off-label use | 3110003 | |
Pyrexia of unknown origin | off-label use | 7520000 | |
Chronic purulent otitis media | off-label use | 38394007 | DOID:14247 |
Cholangitis | off-label use | 82403002 | DOID:9446 |
Human bite - wound | off-label use | 262555007 | |
Chancroid | off-label use | 266143009 | DOID:13778 |
Diverticulitis of gastrointestinal tract | off-label use | 271366000 | |
Dog bite - wound | off-label use | 283734005 | |
Cat bite - wound | off-label use | 283782004 | |
Acute exacerbation of chronic bronchitis | off-label use | 425748003 | |
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis | off-label use | ||
Diabetic Foot Infection | off-label use | ||
Obstruction of bile duct | contraindication | 30144000 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Infectious mononucleosis | contraindication | 271558008 | DOID:8568 |
Pseudomembranous enterocolitis | contraindication | 397683000 |
Species | Use | Relation |
---|---|---|
Dogs | Urinary tract infections caused by Escherichia coli | Indication |
Dogs | Skin and soft tissue infections caused by beta-lactamase producing Staphylococcus aureus | Indication |
Dogs | Skin and soft tissue infections caused by Staphylococcus spp | Indication |
Dogs | Skin and soft tissue infections caused by Streptococcus spp | Indication |
Dogs | Skin and soft tissue infections caused by Escherichia coli | Indication |
Dogs | Skin and soft tissue infections caused by Pasteurella spp | Indication |
Cats | Urinary tract infections caused by Escherichia coli | Indication |
Cats | Skin and soft tissue infections caused by beta-lactamase producing Staphylococcus aureus | Indication |
Cats | Skin and soft tissue infections caused by Staphylococcus spp | Indication |
Cats | Skin and soft tissue infections caused by Streptococcus spp | Indication |
Cats | Skin and soft tissue infections caused by Escherichia coli | Indication |
Cats | Skin and soft tissue infections caused by Pasteurella spp | Indication |
Cats | Periodontal infections due aerobic and anaerobic bacteria | Indication |
Product | Applicant | Ingredients |
---|---|---|
CLAVAMOX CHEWABLE Tablets, CLAVAMOX tablets | Zoetis Inc. | 2 |
Clavamox Drops | Zoetis Inc. | 2 |
Clavacillin | Dechra Veterinary Products LLC | 2 |
Amoxicillin and Clavulanate Potassium for Oral Suspension | Dechra Veterinary Products LLC | 2 |
Amoxicillin and Clavulanate Potassium Tablets | Cronus Pharma Specialities India Private Limited | 2 |
Amoxicillin and Clavulanate Potassium for Oral Suspension | Cronus Pharma Specialities India Private Limited | 2 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.07 | acidic |
pKa2 | 13.53 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-lactamase TEM | Enzyme | INHIBITOR | IC50 | 10.19 | WOMBAT-PK | CHEMBL | |||
Beta-lactamase | Enzyme | IC50 | 7.82 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 4 | CHEMBL | |||||
Beta-lactamase SHV-1 | Enzyme | IC50 | 7.55 | CHEMBL | |||||
Beta-lactamase | Enzyme | Kd | 6.40 | CHEMBL | |||||
Beta-lactamase OXA-1 | Enzyme | IC50 | 5.49 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 6.10 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 8.05 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7.15 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7.07 | CHEMBL | |||||
Carbapenem-hydrolizing beta-lactamase SFC-1 | Enzyme | IC50 | 4.14 | CHEMBL | |||||
Carbepenem-hydrolyzing beta-lactamase KPC | Enzyme | Ki | 4.96 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7.17 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 8.05 | CHEMBL | |||||
Beta-lactamase SHV-1 | Enzyme | IC50 | 6.77 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 5.07 | CHEMBL | |||||
Beta-lactamase GES-13 | Enzyme | IC50 | 7 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 5.76 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7.70 | CHEMBL | |||||
Class D beta-lactamase | Unclassified | IC50 | 5.70 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 8 | CHEMBL | |||||
Beta-lactamase SHV-5 | Enzyme | Ki | 4.60 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7 | CHEMBL | |||||
Beta-lactamase | Enzyme | MPC | 8.72 | WOMBAT-PK | |||||
Beta-lactamase | Enzyme | IC50 | 7.44 | CHEMBL |
ID | Source |
---|---|
N0000005804 | NUI |
D02370 | KEGG_DRUG |
61177-45-5 | SECONDARY_CAS_RN |
21216 | RXNORM |
4018406 | VANDF |
4019680 | VANDF |
C0055860 | UMLSCUI |
CHEBI:48947 | CHEBI |
J01 | PDB_CHEM_ID |
CHEMBL777 | ChEMBL_ID |
DB00766 | DRUGBANK_ID |
CHEMBL1003 | ChEMBL_ID |
D019818 | MESH_DESCRIPTOR_UI |
5280980 | PUBCHEM_CID |
4948 | INN_ID |
11128 | IUPHAR_LIGAND_ID |
23521W1S24 | UNII |
4463 | MMSL |
d04405 | MMSL |
002808 | NDDF |
002809 | NDDF |
395938000 | SNOMEDCT_US |
395939008 | SNOMEDCT_US |
412318009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2270 | TABLET, CHEWABLE | 28.50 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2270 | TABLET, CHEWABLE | 28.50 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2272 | TABLET, CHEWABLE | 57 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2272 | TABLET, CHEWABLE | 57 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2274 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2274 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2275 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2275 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2277 | POWDER, FOR SUSPENSION | 28.50 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2277 | POWDER, FOR SUSPENSION | 28.50 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2279 | POWDER, FOR SUSPENSION | 57 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2279 | POWDER, FOR SUSPENSION | 57 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-8675 | POWDER, FOR SUSPENSION | 42.90 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-8675 | POWDER, FOR SUSPENSION | 42.90 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0143-9249 | TABLET | 125 mg | ORAL | ANDA | 28 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0143-9853 | SUSPENSION | 42.90 mg | ORAL | ANDA | 28 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0143-9981 | POWDER, FOR SUSPENSION | 28.50 mg | ORAL | ANDA | 27 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0143-9982 | POWDER, FOR SUSPENSION | 57 mg | ORAL | ANDA | 27 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-1619 | TABLET, CHEWABLE | 28.50 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-1643 | TABLET, CHEWABLE | 57 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-1831 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-1852 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-1874 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0781-1943 | TABLET, MULTILAYER, EXTENDED RELEASE | 62.50 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-6102 | POWDER, FOR SUSPENSION | 28.50 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-6104 | POWDER, FOR SUSPENSION | 57 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-6139 | SUSPENSION | 42.90 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-931 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 27 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-951 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 26 sections |
AMOXICILLIN AND CLAVULANATE POTASSIUM | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16590-019 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 26 sections |